On June 10, 2021, Eli Lilly became the third manufacturer to response to HRSA’s May 17th Cease and Desist letter on 340B drug pricing. The response details Eli Lilly’s rejection of HRSA’s reasoning in its Cease and Desist letter, arguing that the agency’s reasoning is inconsistent with both its prior conduct and the 340B statute. Eli Lilly states that it will not comply with HRSA’s request to provide an update on its 340B pricing plan and will instead await the final resolution of the issue by the courts. The letter urges HRSA to rescind its May 17th letter. Sanofi and Novartis have submitted similar responses.